• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与多发性硬化症复发相关的直接和间接成本负担:多发性硬化症患者及其配偶照顾者的超额成本。

Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.

机构信息

Groupe d'analyse, Ltée, Montréal, QC, Canada.

出版信息

J Neurol Sci. 2013 Jul 15;330(1-2):71-7. doi: 10.1016/j.jns.2013.04.007. Epub 2013 May 3.

DOI:10.1016/j.jns.2013.04.007
PMID:23647840
Abstract

BACKGROUND

MS relapses are unpredictable and can be concerning to patients and their caregivers.

OBJECTIVE

To assess the direct and indirect cost burden associated with relapses of different severities in MS patients and with MS relapse frequency on spouse caregivers.

METHODS

Using a U.S. insurance claims and employee disability database (1999-2011), we studied adult MS patients (ICD-9-CM: 340.x) and their spouse caregivers. A previously published algorithm to identify relapses was used to stratify: (1) MS patients into cohorts of no, low/moderate, and high severity relapse based on the most severe relapse within one year of follow-up (if any); (2) caregivers into cohorts of no, less, and more frequent relapses based on the overall frequency of relapses of their spouse. Adjusted cost differences and 95% confidence intervals evaluating the yearly incremental costs at 12 months of follow-up (MS patients) and overall (caregivers) associated with relapses are reported.

RESULTS

Among the 9421 MS patients (N: no relapse=7686; low/moderate severity relapse=1220; high severity relapse=515) identified, both relapse cohorts incurred significantly higher annual incremental direct costs than the no relapse cohort (low/moderate severity=$8269 [6565-10,115]; high severity=$24,180 [20,263-28,482]) and indirect costs (low/moderate severity=$1429 [759-2147]; high severity=$2714 [1468-4035]). More frequent relapses versus no relapse also translated into a significantly greater cost burden for caregivers (direct+indirect=$1725 [376-2885]) but less frequent relapses did not.

CONCLUSIONS

Relapse severity was significantly and increasingly associated with greater direct and indirect costs in MS patients. More frequent relapses also translated into a significant cost burden in spouse caregivers.

摘要

背景

多发性硬化症(MS)的复发是不可预测的,这会让患者及其护理人员感到担忧。

目的

评估不同严重程度的 MS 患者复发以及患者复发频率对配偶护理人员带来的直接和间接经济负担。

方法

我们使用了美国的保险索赔和员工残疾数据库(1999-2011 年),研究了成年 MS 患者(ICD-9-CM 编码:340.x)及其配偶护理人员。我们使用了一种已发表的算法来识别复发,该算法将 MS 患者分为无复发、低/中度复发和高复发严重程度的队列,这是基于在随访一年内最严重的复发情况(如果有的话);根据配偶的总体复发频率,将护理人员分为无复发、复发较少和复发更频繁的队列。报告了在 12 个月的随访(MS 患者)和总体(护理人员)时,与复发相关的调整后成本差异和 95%置信区间,以评估每年的增量成本。

结果

在确定的 9421 名 MS 患者(无复发者=7686 例;低/中度严重程度复发者=1220 例;高严重程度复发者=515 例)中,复发队列的年度增量直接成本均显著高于无复发队列(低/中度严重程度复发者为 8269 美元[6565 美元至 10115 美元];高严重程度复发者为 24180 美元[20263 美元至 28482 美元])和间接成本(低/中度严重程度复发者为 1429 美元[759 美元至 2147 美元];高严重程度复发者为 2714 美元[1468 美元至 4035 美元])。与无复发相比,更频繁的复发也给配偶护理人员带来了更大的经济负担(直接加间接费用=1725 美元[376 美元至 2885 美元]),但不太频繁的复发则不会。

结论

复发的严重程度与 MS 患者的直接和间接成本显著增加相关。更频繁的复发也给配偶护理人员带来了显著的经济负担。

相似文献

1
Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.与多发性硬化症复发相关的直接和间接成本负担:多发性硬化症患者及其配偶照顾者的超额成本。
J Neurol Sci. 2013 Jul 15;330(1-2):71-7. doi: 10.1016/j.jns.2013.04.007. Epub 2013 May 3.
2
Costs and quality of life of multiple sclerosis in Switzerland.瑞士多发性硬化症的成本与生活质量
Eur J Health Econ. 2006 Sep;7 Suppl 2:S86-95. doi: 10.1007/s10198-006-0383-9.
3
Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.美国多发性硬化症患者药物依从性对严重复发、直接和间接成本的影响。
J Med Econ. 2012;15(3):601-9. doi: 10.3111/13696998.2012.667027. Epub 2012 Mar 1.
4
Economic costs associated with an MS relapse.与多发性硬化症复发相关的经济成本。
Mult Scler Relat Disord. 2014 Nov;3(6):678-83. doi: 10.1016/j.msard.2014.09.002. Epub 2014 Sep 16.
5
Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands.多发性硬化症研究中的治疗经验、负担和未满足的需求(论坛):荷兰多发性硬化症患者的成本和效用。
J Med Econ. 2013 Jul;16(7):939-50. doi: 10.3111/13696998.2013.807267. Epub 2013 Jun 12.
6
Costs and quality of life in multiple sclerosis patients with spasticity.痉挛性多发性硬化症患者的成本和生活质量。
Acta Neurol Scand. 2014 Jan;129(1):13-20. doi: 10.1111/ane.12139. Epub 2013 May 18.
7
Costs and quality of life in multiple sclerosis in The Netherlands.荷兰多发性硬化症的成本与生活质量。
Eur J Health Econ. 2006 Sep;7 Suppl 2:S55-64. doi: 10.1007/s10198-006-0378-6.
8
Costs and quality of life of multiple sclerosis in Austria.奥地利多发性硬化症的成本与生活质量
Eur J Health Econ. 2006 Sep;7 Suppl 2:S14-23. doi: 10.1007/s10198-006-0382-x.
9
Costs and quality of life of multiple sclerosis in Germany.德国多发性硬化症的成本与生活质量
Eur J Health Econ. 2006 Sep;7 Suppl 2:S34-44. doi: 10.1007/s10198-006-0384-8.
10
Costs and quality of life of multiple sclerosis in Italy.意大利多发性硬化症的成本与生活质量
Eur J Health Econ. 2006 Sep;7 Suppl 2:S45-54. doi: 10.1007/s10198-006-0385-7.

引用本文的文献

1
Economic burden of multiple sclerosis in the United States: A systematic literature review.美国多发性硬化症的经济负担:一项系统文献回顾。
J Manag Care Spec Pharm. 2023 Dec;29(12):1354-1368. doi: 10.18553/jmcp.2023.23039. Epub 2023 Nov 17.
2
Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.使用奥瑞珠单抗进行一线治疗与二线或后续治疗的多发性硬化症患者的真实世界临床和经济结果
Neurol Ther. 2023 Oct;12(5):1709-1728. doi: 10.1007/s40120-023-00523-3. Epub 2023 Jul 17.
3
Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study in British Columbia, Canada, 2001-2020.
与多发性硬化症相关的直接医疗保健费用:2001-2020 年加拿大不列颠哥伦比亚省的一项基于人群的队列研究。
Neurology. 2023 Feb 28;100(9):e899-e910. doi: 10.1212/WNL.0000000000201645. Epub 2022 Nov 30.
4
Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease.纳入社会成本是否会改变经济评估建议?一项针对多发性硬化症的系统评价。
Eur J Health Econ. 2023 Mar;24(2):247-277. doi: 10.1007/s10198-022-01471-9. Epub 2022 May 20.
5
Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis.注射用促肾上腺皮质激素治疗多发性硬化急性加重期的成本效益分析
Clinicoecon Outcomes Res. 2021 Oct 11;13:883-892. doi: 10.2147/CEOR.S330118. eCollection 2021.
6
Epstein-Barr Virus Infection in the Development of Neurological Disorders.爱泼斯坦-巴尔病毒感染与神经系统疾病的发展
Drug Discov Today Dis Models. 2020 Fall;32(Pt A):35-52. doi: 10.1016/j.ddmod.2020.01.001. Epub 2020 Feb 19.
7
Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients.评估初治多发性硬化症患者疾病修正治疗的治疗模式、复发情况、医疗资源利用及成本。
Clinicoecon Outcomes Res. 2021 Jan 22;13:65-75. doi: 10.2147/CEOR.S288296. eCollection 2021.
8
Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis.接受多发性硬化症疾病修正治疗的在职患者的生产力损失及相关成本
Pharmacoecon Open. 2021 Mar;5(1):23-34. doi: 10.1007/s41669-020-00233-8. Epub 2020 Oct 13.
9
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis.真实世界证据:多发性硬化症患者的社会经济复发成本。
Pharmacoeconomics. 2020 Aug;38(8):883-892. doi: 10.1007/s40273-020-00917-3.
10
A Systematic Review of the Incidence, Prevalence, Costs, and Activity and Work Limitations of Amputation, Osteoarthritis, Rheumatoid Arthritis, Back Pain, Multiple Sclerosis, Spinal Cord Injury, Stroke, and Traumatic Brain Injury in the United States: A 2019 Update.美国肢体截肢、骨关节炎、类风湿性关节炎、腰痛、多发性硬化症、脊髓损伤、中风和创伤性脑损伤的发病率、患病率、成本以及活动和工作受限的系统评价:2019 年更新。
Arch Phys Med Rehabil. 2021 Jan;102(1):115-131. doi: 10.1016/j.apmr.2020.04.001. Epub 2020 Apr 24.